Opiranserin (INNTooltip International Nonproprietary Name; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50Tooltip Half-maximal inhibitory concentration = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50Tooltip Half-maximal inhibitory concentration = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain.

[1][2][3][4] As of April 2017, it is in phase II clinical trials for this indication.

[3] The INNTooltip International Nonproprietary Name of the drug was issued in 2017.

[2] Approved for post-operative pain management in South Korea in December,2024.